insulin degludec vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecinsulin icodec
HbA1c, change-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116—Not posted · NCT05013229
Fasting plasma glucose, change-4.1 vs -2.6vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not posted · NCT05802862—Not posted · NCT05013229

HbA1c, change

insulin degludec
-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
insulin icodec
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

insulin degludec
2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
insulin icodec
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

insulin degludec
-4.1 vs -2.6vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
insulin icodec
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. insulin degludec: 10 of 10 rows · insulin icodec: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludec
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wka,b,c,d
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1.23% (n=91) @ 52wkb,c,d
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
HbA1c Change mmol/Mol
absolute change · mmol/mol
-6.18 vs -5.89 NovoRapid mmol/mol @ 16wke,f,c,g
NCT04588259 · Phase 3 · registry result, not featured evidence
-14.51 vs -12.54 Insulin Glargine mmol/mol @ 26wke,f,c,g
NCT03751657 · Phase 2 · registry result, not featured evidence
Hypoglycemia Episodes Level 2
event count · count
23 vs 53 Insulin Icodec count @ 31wkb,c
NCT04795531 · Phase 3 · registry result, not featured evidence
53 vs 23 Insulin Degludec count @ 31wkb,c
NCT04795531 · Phase 3
2 other source trials
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3
event count · count
25 vs 53 Insulin Icodec count @ 31wkb,c
NCT04795531 · Phase 3 · registry result, not featured evidence
53 vs 25 Insulin Degludec count @ 31wkb,c
NCT04795531 · Phase 3
2 other source trials
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 3
event count · count
280 vs 472 Insulin Glargine countb,c,h
NCT01959529 · Phase 3
1 other source trial
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 2 Insulin Degludec count @ 31wkb,c,h
NCT04795531 · Phase 3
2 other source trials
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
SMBG 9-point
absolute change · mmol/L
-3.84 vs -3.46 Liraglutide mmol/L @ 52wka,e,b,c,i
NCT02607306 · Phase 3 · registry result, not featured evidence
show 1 more dose
-4.6 vs -3.46 Liraglutide mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-2.7 vs -2.26 Insulin Glargine mmol/L @ 26wke,b,c,i
NCT03751657 · Phase 2 · registry result, not featured evidence
Dropout rate
21.5%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
8.3%k
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
—k
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
15.1%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
8.3%k
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
once dailyj
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence
k
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 32 weeks versus 52 weeks.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 16 weeks versus 26 weeks.
  8. hThe assessment timepoint is not available for both results.
  9. iAssessment timepoints differ: 52 weeks versus 26 weeks.
  10. jPopulation comparability has not been reviewed for 25 of these studies.
  11. kPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted
Clinically Significant Hypoglycemia Event Incidence 3.7% (n=82) vs 1.3% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
Severe Hypoglycemia Event Incidence 0% (n=82) vs 0% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
Severe Hyperglycemia Event Incidence 63.4% (n=82) vs 59.5% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted

+ 102 further endpoints in the CSV export.

insulin icodec

Time in Range 71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wk
absolute value · percentage points
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
19.94% (n=202) vs 11.04% (n=198) Insulin Glargine @ 26wk
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
63.13% (n=238) vs 59.5% (n=239) Insulin Degludec @ 26wk
NCT04770532 · Phase 3
Time Below Range 0.27 vs 0.21 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 26.86 vs 32.27 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
35.52 vs 39.71 Insulin Degludec % of time @ 26wk
NCT04770532 · Phase 3
30.47 vs 31.3 Insulin Glargine % of time @ 26wk
NCT04880850 · Phase 3
Time Above Range -20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wk
absolute value · percentage points
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time Below 54 mg/dL 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wk
absolute value · percentage points
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below 54 mg/dL 0.73 vs 0.61 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
SMBG 7-point -1.69 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
PPG Excursion -1.27 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.29 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Weight -3.85 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · insulin icodec's landscape